direct factor Xa inhibitors

Browse trials
V2  
List  

treatment    comparator  All cause death All cause death Coronary death Coronary event Coronary event Coronary event Adverse events Bleeding Cardiovascular death Cardiovascular death Major bleeding Major bleeding Minor bleeding Haemmorhagic stroke Haemmorhagic stroke Fatal stroke Fatal stroke Non fatal stroke Non fatal MI Fatal bleeding thrombo-embolic event (cerebral or systemic) ischemic stroke  hypertransaminasemia intracranial hemorrhage TE event or ischemic stroke or systemic embolism stroke (fatal and non fatal)  stroke (fatal and non fatal)  myocardial infarction (fatal and non fatal)  myocardial infarction (fatal and non fatal)  Deep vein thrombosis  cardiovascular events cardiac event (fatal and non fatal ) proximal DVT  distal DVT  non-fatal pulmonary embolism  asymptomatic DVT  total VTE and all-cause mortality  fatal pulmonary embolism  Symptomatic venous thromboembolism (DVT, PE) major VTE (fatal and non fatal DVT,PE)  recurrent DVT Gastrointestinal major bleeding  Non-lifethreatening major bleeding  Lifethreatening major bleeding Acute coronary syndrome Symptomatic deep-vein thrombosis major or clinically relevant non-major bleeding any bleedings stent thrombosis  systemic thrombo-embolic complication  major or minor bleeding  VTE     
Edoxabanatrial fibrillation, in all type of patients vs warfarin standard doseNSNS----- by 13% by 14% by 14% by 20% by 20% by 16% by 53% by 53% NSNS-- by 45% NSNS- by 53% -NSNSNSNS------------ by 23% - by 49% -- by 14% --NS--
Edoxabanthrombosis prevention, in all type of patients vs enoxaparin (short duration)--------------------------------NS by 64% - by 62% --- by 66% -----NS------
Dabigatranacute coronary syndrome, in all type of patients vs placebo---NSNSNS----------------------------------------------
Apixabanacute coronary syndrome, in all type of patients vs placeboNSNS-NSNSNS--NSNS by 153% by 153% -------NS-NS-----NSNS-NSNS-------------- by 139% by 121% NS- by 174% -
Apixabanatrial fibrillation, in all type of patients vs warfarin standard dose by 11% [demonstrated] by 11% [demonstrated]-NSNSNS- by 23% -- by 30% [demonstrated] by 30% [demonstrated]- by 49% by 49% ----- by 20% [demonstrated]NS- by 58% - by 21% by 21% NSNS------------NS---- by 30% --NS--
Apixabanatrial fibrillation, in all type of patients vs aspirinNSNS-NSNSNS--NSNSNSNS by 27% NSNS----NS by 54% by 63% -NS- by 54% by 54% NSNS------------NS----------
Apixabanthrombosis prevention, in all type of patients vs enoxaparinNSNS-NSNSNS----NSNS---------------NSNS by 68% -- by 65% -NS by 67% by 64% -NS by 60% -----NSNS-----
Apixabanthrombosis prevention, in all type of patients vs enoxaparin (europe regimen)NSNS-NSNSNS----NSNS---------------NSNS by 40% -- by 65% --- by 38% -NS by 50% -----NSNS-----
Apixabanthrombosis prevention, in all type of patients vs enoxaparin (US regimen)NSNS-NSNSNS----NSNS---------------NSNSNS--NS--NSNS-NSNS-----NS by 33% NS----
Otamixabanacute coronary syndrome, in all type of patients vs unfractionated heparin----------------------------------------------------
Rivaroxabanacute coronary syndrome, in all type of patients vs placebo by 48% by 48% -NSNSNS-- by 49% by 49% by 304% by 304% -------NS------- by 33% by 33% - by 37% NS-------------- by 106% by 100% -- by 75% -
Rivaroxabanatrial fibrillation, in all type of patients vs warfarin standard doseNSNS-NSNSNS--NSNSNSNS- by 42% by 42% NSNS-- by 50% NSNS- by 33% -NSNSNSNS------------ by 46% - by 31% --NS--NS--
Rivaroxabancardiovascular prevention, in secondary prevention vs aspirin by 8100% by 8100% ------ by 7700% by 7700% ----- by 7700% by 7700% ---- by 5000% --- by 5700% by 5700% -------------------------
Rivaroxabanthrombosis prevention, in all type of patients vs enoxaparinNSNS-NSNSNS----NSNS----------------- by 77% -- by 97% NSNS- by 70% -NS by 88% ------------
Rivaroxabanthrombosis prevention, in all type of patients vs enoxaparin (europe regimen)NSNS-NSNSNS----NSNS---------------NSNS by 47% --NS by 47% NS- by 49% - by 66% by 62% ------------
Rivaroxabanthrombosis prevention, in all type of patients vs enoxaparin (short duration)NSNS-NSNSNS----NSNS----------------- by 74% -- by 81% by 66% NS- by 73% - by 80% by 88% ------NS-----
Rivaroxabanthrombosis prevention, in all type of patients vs enoxaparin (US regimen)NSNS-NSNSNS----NSNS---------------NSNS--- by 77% NSNSNS by 31% -NSNS-----NSNS-----
Ximelagatranacute coronary syndrome, in all type of patients vs placebo----------------------------------------------------
Ximelagatranvenous thrombosis, in all type of patients vs discontinuationNSNS--------NSNS-----------------------------------NS--- by 76%

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons